Skip to content

About SpectraCure
The Product
- Method
- Patent
Newsroom
Investor
Governance
Contact
- Career

About SpectraCure
The Product
- Method
- Patent
Newsroom
Investor
Governance
Contact
- Career

SV
EN

General meetings

Start / Governance / General meetings

Governance report
Articles of Association
General meetings
Nomination committee
Board
Auditor
Management

Governance report
Articles of Association
General meetings
Nomination committee
Board
Auditor
Management

Notice of the Annual General Meeting

Kallelse årsstämma SpectraCure 2025 (Swedish)

Appendices

Valberedningens fullständiga förslag och motiverade yttrande 2025 (Swedish)

Fullmaktsformulär SpectraCure 2025 (Swedish)

Information om nya föreslagna ledamöter (Swedish)

Minutes of the Meeting (in Swedish)

Minutes of the meeting 2025.05.30
Minutes of the meeting 2024.05.16
Minutes of the meeting 2023.05.16
Minutes of the meeting 2022.05.12
Minutes of the meeting 2021.05.18
Minutes of the meeting 2020.05.28
Minutes of the meeting 2019.05.23
Minutes of the meeting 2018.05.23
Minutes of the meeting 2017.05.23
Minutes of the meeting 2016.05.18
Minutes of the meeting 2015.06.12

Newsroom
Investor
Governance
Career
Contact

Newsroom
Investor
Governance
Career
Contact

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.

Facebook Linkedin Envelope

Privacy policy
Cookie information

Privacy policy
Cookie information